Published in Clinical Trials Week, December 6th, 2004
Under the terms of the amended agreement, Vitex will issue approximately 54 million shares at closing to complete the merger and acquire all Panacos outstanding shares. Panacos will have the opportunity to receive approximately 31 million additional Vitex shares, for a total of 85 million...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Clinical Trials Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.